database / gh-secretagogue

Tesamorelin

also known as Egrifta

approved gh-secretagogue endocrinemetabolic sequence not characterised

361 heavy atoms · 729 bonds · drag to pan, scroll to zoom C221N72O67S1

Skeletal structure drawn from the computed atomic coordinates in PubChem CID 16137828. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.

Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.

Sequence

Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.

GHRH(1-44) analogue bearing an N-terminal trans-3-hexenoyl group; the acyl modification places it outside plain one-letter representation here.

Molecular data

Chemical fields come from the PubChem compound record; computed values are derived from the sequence shown above.
molecular formula	C221H366N72O67S
molecular weight	5136 Da (PubChem)
computed backbone mass	not characterised
length	not characterised
net charge (pH 7.4)	not characterised
mean hydropathy	not characterised
half-life	not characterised
delivery route	subcutaneous
PubChem CID	16137828
PDB	not characterised
UniProt parent	P01286

Mechanism

GHRH analogue; approved for HIV-associated lipodystrophy.

Reported targets: GHRHR

Experimental structure

No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.

Parent protein

Based on full-length GHRH(1-44). UniProt P01286 · 108 aa

Reported effects

Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.

Reported observations and the corpus they are drawn from.
reported outcome	where it appears
visceral fat reduction	P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence i… Open forum infectious diseases 2026
IGF-1 elevation	Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV… BMJ open 2026

Registered trials

Records from ClinicalTrials.gov. Listed for reference — this project sponsors no trial and is not involved in any of them.
NCT	title	status	phase
NCT01579695	Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®	TERMINATED	—
NCT01264497	Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes	COMPLETED	PHASE2
NCT03226821	Body Composition and Adipose Tissue in HIV	TERMINATED	PHASE4
NCT01591902	Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®	TERMINATED	PHASE4
NCT01632592	Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Horm	WITHDRAWN	NA

Literature (8)

P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants — Open forum infectious diseases 2026